An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study will continue to evaluate the safety & efficacy of Certolizumab Pegol (CZP) for 6
months in Chinese subjects with active Rheumatoid Arthritis who participated in RA0044.